Clinical Trials

This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This research trial studies the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT)and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase III trial compares the addition of apalutamide, with or without targeted radiation therapy, to standard of care treatment versus standard of care treatment alone in patients with prostate cancer biochemical recurrence (a rise in the blood level of prostate-specific antigen [PSA] after treatment with surgery or radiation). Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT), may help doctors look for cancer that has spread to the pelvis. Androgens can cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET/CT results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W Stout St

Rice Lake, WI 54868

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Rice Lake

1700 W Stout St

Rice Lake, WI 54868

MMC - Stevens Point Campus

4100 WI-66

Stevens Point, WI 54482

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI 54476

Chronic hypertension (CHTN), the most common major medical disorder encountered in pregnancy, is a significant cause of maternal and perinatal (fetal and newborn) death and morbidities. Whereas anti-hypertensive treatment is recommended for the general non-pregnant population, it is highly controversial whether over 70-80% of pregnant women with CHTN classified as mild (BP <160/110 mmHg) should be treated. Reports associate antihypertensive treatment with fetal growth restriction (FGR) and/or small-for gestational age (SGA) babies, which are risk factors for stillbirth and impaired childhood neurodevelopment and growth, without clear benefits for mother or offspring. Compared to women without CHTN, several severe adverse outcomes are increased in women with CHTN. Preeclampsia superimposed (SI) on CHTN complicates 30-50% of pregnancies with CHTN and is the most important mediator of other adverse outcomes. Emerging data associate preeclampsia with increased rates of neurodevelopmental abnormalities, altered growth and higher blood pressure in childhood (as well as maternal cardiovascular diseases in later life) but these data are limited. Furthermore, most of these studies have evaluated de novo preeclampsia (no CHTN) and not SI preeclampsia. The long-term harms vs. benefits of antihypertensive therapy for mild CHTN early in pregnancy and potential harm from SI preeclampsia, as well as the roles of other factors such as duration and severity of hypertension are unknown.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

VHIRB-The Chronic Hypertension and Pregnancy (CHAP) Project randomized pregnant women with mild chronic hypertension (CHTN) to usual care (i.e. antihypertensive therapy only if the patient experienced severe hypertension defined as systolic blood pressure (SBP) =160 mmHg or diastolic blood pressure (DBP) =105 mmHg) or to intervention (i.e. antihypertensive therapy to goal BP < 140/90 mmHg).

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

The main objective of the MAGICAL ISR Trial is to assess the efficacy and safety of the MagicTouch™ sirolimus-coated balloon during PCI primary endpoint of TLF at 12 months in patients with ISR lesions.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449